Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label follow-on safety study of MBP8298 in secondary progressive multiple sclerosis
NL-OMON32699Phase 2Active, not recruiting
- Sponsor
- ICON
- Start
- Dec 2008
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dirucotide in secondary-progressive multiple sclerosis (SPMS), sponsored by ICON. Primary endpoints: Adverse events, Blood pressure and 5 more. Started Dec 2008; status: active, not recruiting.
02
Drugs
dirucotide
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NL-OMON32699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32699.